IDEXX Sees 12% Q4 Organic Growth on 1,900 inVue Placements, Guides 8–10% 2026
IDEXX Laboratories reported Q4 organic revenue rising 12% with 90 basis points of margin expansion, fueled by 1,900 inVue Dx placements and 6,000 Cancer Dx customers, 18% new. It plans 8–10% organic growth in companion animal diagnostics, targets ~5,500 inVue placements, 30–80 bps margin gain and ~4% price realization.
1. Q4 Performance
IDEXX reported 12% organic revenue growth for Q4 with comparable operating margin improving by 90 basis points. Executives cited double-digit top-line gains supported by premium instrument placements reaching record levels and a 12% expansion of the install base year over year.
2. Cancer Dx and inVue Momentum
The inVue Dx Analyzer achieved 1,900 incremental placements in Q4, contributing to over 6,000 for full-year 2025. Cancer Dx added 6,000 customers, of which 18% were new to IDEXX Reference Laboratories, underscoring innovation-driven demand.
3. 2026 Guidance and Outlook
For 2026, IDEXX targets 8–10% organic growth in companion animal diagnostic revenue, about 5,500 inVue Dx placements, and 30–80 basis points of operating margin improvement. Net price realization is expected around 4%, reflecting a strategic value-based pricing approach.
4. Operational and Demographic Drivers
Executives highlighted stabilizing non-wellness visits and improved diagnostic intensity, with clinical blood-testing frequency rising 100 basis points. The aging pet population acquired during the pandemic is seen as a sustained tailwind for diagnostic services growth.